Core Viewpoint - A class action lawsuit has been filed against Eos Energy Enterprises, Inc. for alleged misleading statements and failures to disclose critical operational issues during the class period from November 5, 2025, to February 26, 2026 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Eos Energy was unable to meet its production and capacity utilization targets as previously guided [5]. - It is alleged that Eos Energy's battery line experienced downtime significantly above industry norms and internal forecasts [5]. - The company faced delays in achieving quality targets for its automated bipolar production, and its systems were inadequate for providing accurate guidance and timely disclosures [5]. Group 2: Investor Information - Investors who purchased Eos Energy securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must be appointed by May 5, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. for the period between June 16, 2025, and January 8, 2026, due to alleged misleading statements regarding the company's New Drug Application for Anaphylm [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Aquestive made false and/or misleading statements and failed to disclose the true state of its New Drug Application for Anaphylm, particularly regarding the human factors involved in the use of its sublingual film [5]. - Investors who purchased Aquestive securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the Court by May 4, 2026, to represent other class members in directing the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PayPal Holdings, Inc. common stock between February 25, 2025, and February 2, 2026, of the April 20, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought PayPal common stock during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is April 20, 2026, with the lead plaintiff representing other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]. Group 3: Case Background - The lawsuit alleges that PayPal's defendants provided misleading information regarding the company's financial targets for 2027 and the growth potential of its Branded Checkout segment [5]. - It is claimed that while presenting an optimistic outlook, the defendants concealed material adverse facts about PayPal's salesforce capabilities, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Nektar Therapeutics securities during the specified Class Period, indicating potential legal issues for the company and its investors [1]. Group 1: Class Action Details - The class action lawsuit is for purchasers of Nektar securities between February 26, 2025, and December 15, 2025 [1]. - Investors who purchased Nektar securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by May 5, 2026, to represent other class members in the litigation [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been ranked highly for its performance in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made false or misleading statements regarding the REZOLVE-AA trial, including improper enrollment and overstated trial integrity [5]. - The claims suggest that these misrepresentations led to investor damages when the true details became public [5].

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 4, 2026. SO WHAT: If you purchased Aquestive securities during the Class Peri ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Oracle Corporation common stock between June 12, 2025, and December 16, 2025, of the April 6, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Oracle stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by April 6, 2026, to serve as lead plaintiff [2]. - The lawsuit alleges that Oracle made false and misleading statements regarding its AI infrastructure strategy, which led to increased capital expenditures without corresponding revenue growth [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, as many firms may lack the necessary experience [3]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [3]. Group 3: Case Specifics - The lawsuit claims that Oracle's increased spending posed risks to its debt, credit rating, and free cash flow, which were not disclosed to investors [4]. - The misrepresentation of Oracle's business operations and prospects is said to have caused investor damages when the true information became public [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Richtech Robotics Inc. during the specified class period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Richtech Robotics securities between January 27, 2026, and January 29, 2026, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 3, 2026 [3]. - The lawsuit alleges that Richtech made false and misleading statements regarding its relationship with Microsoft, which impacted investors when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Many attorneys at the firm have received recognition from Lawdragon and Super Lawyers, highlighting their expertise in the field [4].

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CoreWeave, Inc. (NASDAQ: CRWV) between March 28, 2025 and December 15, 2025, both dates inclusive (the “Class Period”), of the important March 13, 2026 lead plaintiff deadline. SO WHAT: If you purchased CoreWeave securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased BlackRock TCP Capital Corp. securities between November 6, 2024, and January 23, 2026, of the upcoming lead plaintiff deadline on April 6, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought BlackRock TCP securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by April 6, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements regarding BlackRock TCP's business and operations, including issues with investment valuations and portfolio restructuring [5]. - Specific claims include that BlackRock TCP's unrealized losses were understated and net asset value was overstated, leading to misleading positive statements about the company's prospects [5].

New York, New York--(Newsfile Corp. - March 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2026.SO WHAT: If you purchased Nektar securities during the Class ...